Albinterferon-alpha 2b: a new treatment option for hepatitis C.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

HCV infection affects 180 million people worldwide. Standard therapy combines weekly injections of pegIFN and daily ribavirin (RBV). Albinterferon (albIFN)-α2b is the most advanced in the development of an IFN-based compound.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Expert Opin Biol Ther

Title: Expert opinion on biological therapy

Publisher: Informa Healthcare

ISSN (Electronic): 1744-7682

ISSN (Print): 1471-2598

Publication date (Electronic): Oct 2010

Volume: 10

Issue: 10

Affiliations

[1 ] Medical University of Białystok, Department of Infectious Diseases and Hepatology, 15-540 Białystok, ul. Zurawia 14, Poland. robert.flisiak@umwb.edu.pl

Article

DOI: 10.1517/14712598.2010.521494

PubMed ID: 20828335

SO-VID: b104b4a7-af7b-42e3-b832-4fbe28582442

History

Data availability:

Comments

Comment on this article

scite_

Cited by 7

See all cited by